Glenmark Pharmaceuticals expands U.S. OTC market presence with Olopatadine Eye Drops
Glenmark secures FDA approval for its OTC Olopatadine Hydrochloride eye drops, expanding its U.S. presence in the $50.7M allergy relief market. Read More
Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors. Read More
Game-changer for diabetes? Tandem’s Control-IQ+ automated insulin delivery system now available in the US
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery for type 1 and type 2 diabetes, expanding access to advanced insulin automation in the U.S. Read More
RedHill Biopharma secures $60m licensing agreement with Hyloris for global commercialization of RHB-102
RedHill Biopharma Ltd. has entered into an exclusive licensing agreement with Hyloris Pharmaceuticals SA, granting the Belgian company the rights to develop and commercialize RHB-102 ... Read More
MeiraGTx’s gene therapy trial shows transformative results for children with LCA4 retinal dystrophy
MeiraGTx Holdings plc has announced groundbreaking results from its gene therapy trial targeting Leber congenital amaurosis 4 (LCA4), a severe and rare form of retinal ... Read More
Vertex secures FDA approval for non-opioid pain treatment JOURNAVX
Vertex Pharmaceuticals Incorporated has achieved a significant milestone in the field of pain management with the FDA approval of JOURNAVX (suzetrigine), a first-in-class non-opioid pain ... Read More
Mesoblast issues shares to Osiris Therapeutics after FDA approval of Ryoncil
Mesoblast Limited, a pioneering biotechnology company listed on the Australian Securities Exchange (ASX:MSB), has announced the issuance of 10.2 million ordinary shares to Osiris Therapeutics. ... Read More
FDA approves first generic liraglutide injection for Type 2 diabetes treatment
In a significant milestone for diabetes care, the U.S. Food and Drug Administration (FDA) has approved the first generic equivalent of liraglutide injection, a glucagon-like ... Read More
FDA approves Checkpoint Therapeutics’ Unloxcyt for advanced cSCC
Shares of Checkpoint Therapeutics, Inc. rose 4.6% to $3.84 in post-market trading after the US Food and Drug Administration (FDA) approved Unloxcyt (cosibelimab-ipdl) treatment for ... Read More
FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia
Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in the treatment of classic congenital adrenal hyperplasia ... Read More